VA
IPSC icon

VR Adviser’s Century Therapeutics IPSC Stock Holding History

VR Adviser’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3M Hold
8,695,652
– – 0.65% 23
2026
Q1 		$19.7M Buy
+8,695,652
New +$18.3M 0.73% 25
2025
Q2 		– Sell
-2,498,069
Closed -$1.19M – 34
2025
Q1 		$1.19M Sell
2,498,069
-1,459,117
-37% -$1.1M 0.1% 34
2024
Q4 		$4M Sell
3,957,186
-1,432,073
-27% -$1.95M 0.27% 32
2024
Q3 		$9.22M Hold
5,389,259
– – 0.48% 31
2024
Q2 		$13.7M Buy
5,389,259
+1,984,126
+58% +$6.27M 0.88% 28
2024
Q1 		$14.2M Buy
+3,405,133
New +$14.4M 0.68% 32

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

VR Adviser's IPSC Position: Q2 2026 in Review

VR Adviser held its Century Therapeutics (IPSC) position steady in Q2 2026 at 8,695,652 shares worth $21.3M. The position accounts for 0.65% of the portfolio, ranked #23.

VR Adviser first reported a position in IPSC in Q1 2024 and has held it in 7 quarters since. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • VR Adviser held 8,695,652 shares of Century Therapeutics worth $21.3M as of Q2 2026.
  • VR Adviser left its Century Therapeutics share count unchanged in Q2 2026.
  • Century Therapeutics made up 0.65% of VR Adviser's portfolio in Q2 2026, its #23 holding.
  • VR Adviser first reported a position in Century Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.